A Randomized prospective study comparing efficacy of 0.5% Hyperbaric Levobupivacaine with 0.5% Hyperbaric Bupivacaine for subarachnoid block in Orthopedic lower limb surgeries
Phase 4
- Conditions
- Health Condition 1: W010- Fall on same level from slipping,tripping and stumbling without subsequent striking against objectHealth Condition 2: W183- Other and unspecified fall on samelevelHealth Condition 3: S729- Unspecified fracture of femur
- Registration Number
- CTRI/2023/01/048768
- Lead Sponsor
- TATA MAIN HOSPITA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Adult (Age >= 18 - 60 Years) undergoing orthopedic lower limb surgeries under Subarachnoid block
2 . ASA grade I and II
3.Anticipated Duration of surgery 120 minutes
Exclusion Criteria
1. Patient refusal to participate in study
2. Contraindication to subarachnoid block
3. Patients with height < 150 cm or > 180 cm
4. Patients with BMI >= 30
5. Patient with history of allergy to local anaesthetics
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the onset and duration of sensory block with 0.5% Hyperbaric Levobupivacaine and 0.5% Hyperbaric Bupivacaine after subarachnoid block in adult patients undergoing Orthopedic lower limb surgeries . <br/ ><br>Timepoint: SEPTEMBER 2022 TO JUNE2024
- Secondary Outcome Measures
Name Time Method To determine the following parameters in patients receiving 0.5% Hyperbaric Levobupivacaine and 0.5% Hyperbaric Bupivacaine: <br/ ><br> <br/ ><br> <br/ ><br>1. Onset and duration of motor block <br/ ><br> <br/ ><br>2. Hemodynamic stability <br/ ><br> <br/ ><br>3. Total dose of vasopressor required <br/ ><br> <br/ ><br>4. Incidences of intraoperative complications: Hypotension, Bradycardia, Nausea and Vomiting <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: SEPTEMBER2022 TO JUNE 2024